CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Citius Pharmaceuticals, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.43−0.03 (-7.00%)
Close on Oct 19, 2026
- Market cap
- $11.20M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.0%
1M of 27M shares
Institutional holders
43
13 new, 8 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Leonard L. Mazur | 754,295 | 9.30% | 13D (active) amendment | Nov 25, 2024 |
| CVI Investments, Inc. | 3,008,529 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTXR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 215,537 | 0.79% | $130.30K | −30,621 | 0.00% |
| Vanguard Capital Management LLC | 197,364 | 0.72% | $119.41K | +29,626 | 0.00% |
| Miller Financial Services LLC | 130,000 | 0.47% | $78.59K | +116,000 | 0.06% |
| Citadel Advisors LLC | 124,910 | 0.46% | $75.51K | New | 0.00% |
| Jane Street Group, LLC | 122,837 | 0.45% | $74.26K | +100,314 | 0.00% |
| Vanguard Fiduciary Trust Co | 77,755 | 0.28% | $47.04K | – | 0.00% |
| BlackRock, Inc. | 69,850 | 0.25% | $42.22K | −1 | 0.00% |
| Northern Trust Corp | 62,742 | 0.23% | $37.93K | +18,768 | 0.00% |
| XTX Topco Ltd | 59,199 | 0.22% | $35.79K | +37,904 | 0.00% |
| Asset Advisory Group, Inc. | 59,011 | 0.21% | $35.67K | – | 0.02% |
| BostonPremier Wealth LLC | 28,000 | 0.10% | $16.93K | New | 0.01% |
| UBS Group AG | 26,335 | 0.10% | $15.93K | −28,690 | 0.00% |
| LPL Financial LLC | 25,445 | 0.09% | $15.38K | +400 | 0.00% |
| State Street Corp | 23,271 | 0.08% | $14.07K | – | 0.00% |
| Virtu Financial LLC | 20,836 | 0.08% | $13 | New | 0.00% |
| Arkadios Wealth Advisors | 20,000 | 0.07% | $12.09K | – | 0.00% |
| Two Sigma Investments, LP | 17,494 | 0.06% | $10.58K | +4,356 | 0.00% |
| Sanctuary Advisors, LLC | 11,810 | 0.04% | $7.14K | New | 0.00% |
| Susquehanna International Group, Llp | 11,795 | 0.04% | $7.13K | −25,043 | 0.00% |
| R Squared Ltd | 11,033 | 0.04% | $6.67K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 43 | 1M | 5.0% | 13 / 8 | 9 / 8 | 1M | 0M |
| Q1 2026 | 38 | 1M | 3.6% | 9 / 7 | 6 / 9 | 0M | 1M |
| Q4 2025 | 39 | 2M | 6.3% | 9 / 8 | 7 / 4 | 1M | 0M |
| Q3 2025 | 34 | 1M | 2.3% | 8 / 10 | 4 / 5 | 0M | 1M |
| Q2 2025 | 31 | 1M | 3.4% | 8 / 6 | 6 / 5 | 1M | 0M |
| Q1 2025 | 28 | 1M | 2.3% | 5 / 7 | 7 / 6 | 0M | 0M |
| Q4 2024 | 30 | 1M | 2.2% | 30 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CTXR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 167,738 | 0.61% | $101.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 148,094 | 0.54% | $96.99K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 26,359 | 0.10% | $17.26K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 11,655 | 0.04% | $7.63K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1,862 | -0.01% | -$1.13K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | 410,214 | 1.49% | Sep 23, 2025 |
| Myron Z. Holubiak | Vice Chairman, Director | 79,690 | 0.29% | Aug 12, 2025 |
| Jaime Bartushak | Chief Financial Officer | 60,353 | 0.22% | Nov 12, 2024 |
| Myron Czuczman | Chief Medical Officer | – | – | Nov 12, 2024 |
| Dennis M. McGrath | Director | – | – | Nov 12, 2024 |
| Robert Joseph Smith | Director | – | – | Nov 12, 2024 |
| Suren G. Dutia | Director | – | – | Nov 12, 2024 |
| Eugene Myron Holuka | Director | 2,367 | 0.01% | Nov 12, 2024 |
| Carol Webb | Director | 11,835 | 0.04% | Nov 12, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eugene Myron Holuka Director | Mar 13, 2024 | Tax withholding | −48 | $0.75 | $36 | 2,367 |
| Eugene Myron Holuka Director | Mar 13, 2024 | Option exercise | +2,415 | $0.02 | $48 | 2,415 |
| Carol Webb Director | Mar 4, 2024 | Tax withholding | −236 | $0.77 | $182 | 11,835 |
| Carol Webb Director | Mar 4, 2024 | Option exercise | +12,071 | $0.02 | $241 | 12,071 |
| Myron Z. Holubiak President and CEO, Director, 10% owner | Sep 27, 2019 | Buy | +558,597 | $0.90 | $502.74K | 1,992,243 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Sep 27, 2019 | Buy | +2,234,700 | $0.90 | $2.01M | 10,255,343 |
| Myron Z. Holubiak President and CEO, Director, 10% owner | Apr 3, 2019 | Buy | +129,450 | $1.55 | $200.65K | 1,433,646 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Apr 3, 2019 | Buy | +1,165,048 | $1.55 | $1.81M | 8,020,643 |
| Myron Z. Holubiak President and CEO, Director, 10% owner | Aug 13, 2018 | Buy | +784,314 | $1.28 | $1.00M | 1,304,196 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 13, 2018 | Buy | +3,137,255 | $1.28 | $4.02M | 6,855,595 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Mar 29, 2018 | Buy | +167,504 | $2.99 | $500.84K | 3,718,340 |
| Myron Z. Holubiak President and CEO, Director | Mar 28, 2018 | Buy | +2,915 | $3.09 | $9.01K | 519,882 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Dec 19, 2017 | Buy | +213,106 | $4.69 | $999.47K | 3,550,836 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 24, 2017 | Buy | +11,000 | $2.68 | $29.48K | 3,337,730 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 8, 2017 | Conversion | +1,547,067 | $3.09 | $4.78M | 3,326,730 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 8, 2017 | Buy | +421,400 | $4.13 | $1.74M | 1,779,663 |
| Leonard L. Mazur Director | Mar 30, 2016 | Buy | +5,000,000 | $0.60 | $3.00M | 5,457,143 |
| Leonard L. Mazur Director | Mar 30, 2016 | Other | +15,116,746 | – | – | 20,116,746 |
| Myron Z. Holubiak President and CEO, Director | Mar 30, 2016 | Other | +7,754,497 | – | – | 7,754,497 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.